Valsts: Izraēla
Valoda: angļu
Klimata pārmaiņas: Ministry of Health
OXERUTINES
DEVRIES & CO. LTD
C05CA02
CAPSULES
OXERUTINES 300 MG
PER OS
Not required
STADA ARZNEIMITTEL AG, GERMANY
MONOXERUTIN
MONOXERUTIN
For the adjunctive treatment of varicose veins in all stages.
2014-09-30
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986 This medicine is dispensed without a doctor's prescription VENORUTON CAPSULES 300 MG ACTIVE INGREDIENT Each capsule contains: oxerutines 300 mg Inactive ingredients and allergens: See section 6 ‘Additional information’. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. Take this medicine according to the instructions in the section about dose in this leaflet. Consult your pharmacist if you need additional information. You must contact a doctor if your symptoms worsen or do not improve. 1. WHAT IS THIS MEDICINE INTENDED FOR? Helps treat varicose veins THERAPEUTIC GROUP: bioflavonoids This medicine is used to relieve symptoms resulting from leg vein disorders (chronic venous insufficiency). It has an anti-oedematous effect, which reduces tissue fluid accumulation (swelling or oedema) in the legs and thus relieves symptoms such as heavy, tired legs, tension and tingling in the legs. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • You are sensitive (allergic) to the active ingredient or to any of the other ingredients in this medicine (see section 6). • You are in the first trimester of pregnancy. SPECIAL WARNINGS ABOUT USING THIS MEDICINE Talk to your doctor or pharmacist before taking Venoruton Capsules 300 mg. No special precautions are required. CHILDREN AND ADOLESCENTS No data are available about use in children and adolescents, therefore use is not recommended in this age group. DRUG INTERACTIONS IF YOU ARE TAKING OR HAVE RECENTLY TAKEN OTHER MEDICINES, INCLUDING NONPRESCRIPTION MEDICATIONS AND DIETARY SUPPLEMENTS, TELL YOUR DOCTOR OR PHARMACIST. USING THIS MEDICINE AND FOOD Swallow the medicine with water, during or after a meal. PREGNANCY AND BREAST-FEEDING If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pre Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Venoruton capsules 300 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule contains 300 mg oxerutines. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the adjunctive treatment of varicose veins in all stages. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology 2-3 capsules for a day. Take the capsules unchewed with some liquid during or immediately after meals. The duration of treatment depends on the symptoms. In general, there is no time limit on the duration of use. If symptoms persist, treatment can be continued for a prolonged period of time after consultation with a doctor. Its success depends largely on consequent adherence to the prescribed dosage and duration of treatment. CHILDREN AND ADOLESCENTS UNDER 18 YEARS OF AGE No data are available, therefore the use of oxerutines is not recommended in this age group. PATIENTS WITH CARDIAC, RENAL OR HEPATIC IMPAIRMENT Patients who have oedema of the lower limbs due to cardiac, kidney or liver disorders should not use oxerutines because the efficacy of oxerutines has not been shown in these indications. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance oxerutines or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The use of oxerutines in children is not recommended. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None known. Oxerutines do not show any interaction with anticoagulant drugs of the coumarin type. 4.6 FERTILITY, PREGNANCY AND LACTATION Pregnancy There is insufficient experience with the use of Venoruton 300 in the first months of pregnancy. For the second and third trimesters of pregnancy, various studies with more than 1,400 pregnant women have shown no evidence of harm to the foetus. Use in pregnancy should proceed only when absolutely necessary and from the fourth month of pregnancy onwards. Breast-feedin Izlasiet visu dokumentu